Tagged: longevity
30 results
Ultrahuman
Ultrahuman is a Bengaluru-founded health-technology company building a subscription-free wearable and diagnostics ecosystem centered on its Ring AIR and Ring PRO smart rings. Beyond the ring, the company sells a continuous glucose monitor (M1), a home environmental sensor (Ultrahuman Home) and a blood-biomarker service (Blood Vision), stitching them into a single app that turns sleep, movement, metabolic and recovery data into personalized nudges. Founded in 2019 by Mohit Kumar and Vatsal Singhal, it is now the second-largest smart-ring maker by units sold and is expanding US manufacturing to challenge market leader Oura.
Wei-Wu He
Wei-Wu He is a scientist, inventor, entrepreneur and investor who serves as Executive Chairman and CEO of Human Longevity, Inc., the San Francisco Bay Area precision-health company that pairs whole-genome sequencing with advanced imaging and blood analytics to catch age-related disease early. Trained as a molecular biologist at Baylor College of Medicine with an MBA from Wharton, he was among the first scientists at Human Genome Sciences before building OriGene Technologies into a major research-tools business. Over three decades he has founded or funded dozens of biotech companies through his venture fund Emerging Technology Partners, and he now channels that experience into the science of extending healthy human lifespan.
Function Health
Function Health is an Austin-based membership platform that gives consumers direct access to 100-plus lab tests, optional full-body MRI scans, and AI-generated insights for a flat annual fee. Founded in 2021 and led by CEO Jonathan Swerdlin with physician co-founder Mark Hyman, the company sells a data-first, preventive approach to healthcare aimed at helping members catch problems early and track their biology over time. After a $298M Series B in November 2025 at a $2.5B valuation, Function has become one of the fastest-growing consumer health companies in the US.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
HERVolution Therapeutics
HERVolution Therapeutics is a Copenhagen-based biotechnology company developing immunotherapies that target human endogenous retroviruses (HERVs) - dormant remnants of ancient viruses embedded in human DNA that can reactivate with age and disease. Formerly named InProTher, the company has engineered a proprietary platform that redesigns these 'dark genome' antigens to break immune tolerance, making them visible to the immune system for the first time. Its off-the-shelf vector-based pipeline, led by IPT-001, aims to treat cancer, metabolic disease, and other diseases of aging.
Paratus Sciences
Paratus Sciences is a biotechnology company decoding the extreme biology of bats to discover first-in-class medicines. Bats live long, tolerate viruses, resist cancer, control inflammation and thrive on high-sugar diets - traits they evolved over roughly 65 million years. Paratus integrates cell biology, comparative genomics and informatics to translate these adaptations into drug targets for inflammatory and cardiometabolic diseases. Launched in 2023 with a $100M Series A and dual sites in New York and Singapore, its lead program PS-1001 is a first-in-class pan-inflammasome inhibitor.
PranaX
PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
IM8 (David Beckham & Danny Yeung's health drink startup)
IM8 is a premium longevity supplement brand co-founded by soccer icon David Beckham and serial entrepreneur Danny Yeung, operating as a consumer-health subsidiary of Nasdaq-listed Prenetics. In July 2026, IM8 secured $1 billion in growth financing from General Catalyst's Customer Value Fund (CVF), a non-dilutive facility that funds up to 70% of customer-acquisition spend in exchange for a capped share of cohort revenue rather than equity. Launched in December 2024, IM8 became the fastest-growing premium supplement brand on record, hitting roughly $100 million in annualized revenue within eleven months, and the capital is meant to pour fuel on marketing while ownership stays undiluted.
DexaFit
DexaFit is a health-testing company that turns a quick, low-radiation full-body DXA scan into a broad picture of a person's health - body composition, bone density, visceral fat and metabolic markers. Its AI arm, DexaFit Dx, layers machine learning on top of those same scans to screen for major chronic diseases such as coronary artery disease and type 2 diabetes, aiming to catch them early and non-invasively. Founded in Chicago in 2011 and now operating dozens of centers, DexaFit pairs in-person testing with an app that translates results into longevity scores, disease-risk estimates and trackable goals.
EMAD MOSTAQUE: AI Will RUN Our Countries Soon! We Aren't Ready!
In a wide-ranging interview on the Beyond Tomorrow podcast, Stability AI founder Emad Mostaque argues that within 30-40 years every country will be run by AI, that democracy is in its final decade or two, and that most digital jobs will be economically irrelevant within roughly a thousand days. He puts his personal probability of catastrophe (P-doom) at 50%, warns of intelligence being rationed by a duopoly of powerful labs, and lays out a counter-vision: sovereign, collectively owned 'national champion' AI utilities that give every citizen access to intelligence and a share of the robot fleet. Along the way he explores AI personhood, brain-computer interfaces, longevity escape velocity, quantum computing, and whether we should push a button to eliminate all human suffering.
Fullpower-AI
Fullpower-AI is a Santa Cruz, California science-and-technology company that builds real-time, contactless AI biosensing for sleep, remote patient monitoring, and longevity. Founded in 2005 by camera-phone pioneer Philippe Kahn and Sonia Lee, it operates the Sleeptracker-AI platform and the KOA Large Action Model, powering more than 300,000 Tempur-Pedic smartbeds and over 1.5 million connected devices across 60+ countries, backed by 135+ patents and ISO 27001 certification.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
InsideTracker
InsideTracker is a Cambridge, Massachusetts personalized health and wellness company (legally Segterra, Inc.) that turns your blood, DNA, and wearable data into a science-backed action plan. Founded in 2009 by MIT-trained scientist Dr. Gil Blander, the platform analyzes dozens of blood biomarkers, estimates your biological 'InnerAge,' and recommends specific foods, supplements, and lifestyle changes to optimize performance, healthspan, and longevity. It has become a favorite of athletes and quantified-self enthusiasts and integrates directly with Garmin, Fitbit, Oura, and Apple devices.
OneSkin
OneSkin is a San Francisco biotech and direct-to-consumer skincare company founded by four Brazilian women scientists who set out to slow skin aging at the molecular level. Its flagship OS-01 peptide - identified from a library of 900+ candidates using computational screening and tested on lab-grown human skin models - targets senescent 'zombie' cells that drive wrinkles, thinning and loss of firmness. The company sells topical 'supplements' for the face, eyes, body and sun protection, and frames skin not as a cosmetic surface but as the body's largest organ and a lever on overall healthspan.
Nikolina Lauc
Nikolina Lauc is co-founder and CEO of GlycanAge, a UK-based longevity diagnostics company built on two decades of glycobiology research from her father's laboratory in Zagreb. A serial entrepreneur since 18, she runs a business that translates a blood-based glycan test into a biological age readout, and she has become one of the more visible operators pushing preventive-health testing into the consumer market.
Rony Sellam
Rony Sellam is the CEO of InsideTracker, a Cambridge, Massachusetts based personalized-health company that uses blood biomarkers, DNA and lifestyle data to give consumers actionable recommendations for extending healthspan. A former Deloitte consultant from France by way of Geneva and a longtime healthcare IT executive, he has run InsideTracker for over a decade and helped push the company past 100,000 members and into partnerships with Oura and Fitness SF.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
HexemBio
HexemBio is a New York- and Berkeley-based biotech building what it calls the first blood stem cell rejuvenation therapy. Its Synthetic Human Yolk Sac platform recreates the embryonic environment where blood stem cells first arise, temporarily placing a patient's own aged hematopoietic stem cells into that synthetic young niche before returning them by IV infusion - rather than gene-editing or chemically reprogramming the cells. The company launched publicly in April 2026 with a $10.4M seed round led by Draper Associates, holds an FDA Orphan Drug Designation for a bone-marrow-transplant program in blood cancers, and is targeting first-in-human trials in 2027.
Integrated Biosciences
Integrated Biosciences is a Redwood City biotech founded in 2022 that fuses optogenetics, chemistry, and AI to discover small-molecule drugs for age-related diseases. Its optogenetic screening platform uses light to control cellular biology at millisecond and micron scale, generating clean data to train an explainable-AI drug-discovery engine. The company has published in Nature - including a new structural class of antibiotics - and raised $17.2M in seed funding led by Sutter Hill Ventures.
Mitrix Bio
Mitrix Bio is a Bay Area biotech startup building bioreactor-grown mitochondria - the cell's power plants - packaged into vesicles it calls 'Mitlets' and delivered by injection. Founded by former SLAC accelerator manager Tom Benson, the company treats the slow decline of mitochondria as a root cause of aging and aims to manufacture autologous, young mitochondria at industrial scale so clinicians can regenerate organs, boost immunity and cognition, and extend healthy human lifespan toward 130 years.
NeuroAge Therapeutics
NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.
Rejuvenation Technologies Inc.
Rejuvenation Technologies is a Stanford-spun biotech developing modified-mRNA therapeutics that temporarily switch on telomerase to lengthen telomeres and reverse cellular aging in specific tissues. Its lead programs target fibrotic and age-related diseases such as pulmonary fibrosis, chronic liver disease and bone-marrow failure, delivered by proprietary tissue-targeted lipid nanoparticles. Backed by Khosla Ventures and Y Combinator, the company holds 50+ patents and is advancing toward Phase I clinical readouts.
The Lanby
The Lanby is a membership-based, hospitality-led primary care practice in New York City that reimagines concierge medicine for a modern, prevention-minded patient. Founded in 2021 by breast cancer survivor Chloe Harrouche, it pairs every member with a dedicated care team - a lead physician, wellness advisor, medical assistant, physician associate, and member advocate - to connect the dots across medicine, wellness, and care coordination. For a flat annual fee and no insurance friction, members get unlimited visits, advanced diagnostics with 85+ biomarkers, personalized care plans, and expedited specialist referrals.
Tuktu Care Inc.
Tuktu Care is a Canadian agetech marketplace that uses an AI-driven matching algorithm to pair seniors and families with vetted local companions and service providers. Founded in Vancouver in 2022 after founder Rustam Sengupta's father was diagnosed with dementia, the on-demand platform covers everything from companionship and transportation to housekeeping, overnight care, and post-hospital recovery - typically at 30-40% less than the cost of traditional agencies. A Techstars Future of Longevity company, Tuktu has served 6,000+ customers and built a network of 300+ care providers across Canada, and in March 2026 expanded into the United States with a statewide launch in Vermont.
John Ramunas
John Ramunas, PhD, is the Co-Founder and CEO of Rejuvenation Technologies Inc., a Mountain View, CA biotechnology company pioneering mRNA-based telomere extension therapy to reverse cellular aging. A serial entrepreneur turned neuroscientist, Ramunas spent his PhD at Stanford's Baxter Laboratory for Stem Cell Biology inventing the first safe, nonimmunogenic TERT mRNA drug - a technology now protected by 50+ patents. His company, backed by Khosla Ventures and Y Combinator, is advancing a pipeline targeting fatal orphan diseases including idiopathic pulmonary fibrosis and liver cirrhosis, with the long-term vision of a single therapy taken every few years to prevent age-related disease.
Gordian Biotechnology
Gordian Biotechnology is a South San Francisco in vivo drug discovery company building a high-throughput screening platform that tests hundreds of gene therapies simultaneously inside animals that naturally develop age-related diseases. By pairing 'patient avatar' models with single-cell transcriptomics and machine learning (a stack the company calls Mosaic Screening + Pythia), Gordian aims to predict human clinical outcomes earlier and cure complex diseases of aging.
Alina Su
Alina Su is the co-founder and CEO of Generation Lab, a San Francisco longevity startup building an at-home cheek-swab test that measures biological age across organs and systems. She got her first medical device patent at 15, founded the needle-free injection company NovaXS, left a Harvard Medical School PhD to commercialize aging science from UC Berkeley's Conboy Lab, and made Forbes 30 Under 30 in 2023. Generation Lab has raised about $11M and counts geneticist George Church and Aubrey de Grey among its advisors.
Ashley Zehnder
Ashley Zehnder is the co-founder and CEO of Fauna Bio, a Berkeley biotech mining the genomes of hibernating ground squirrels, bears and 452 other mammal species for drugs that could treat humans. A boarded avian veterinarian with a Stanford PhD in cancer biology, she had her career epiphany while giving chemotherapy to a parrot, when a faculty member asked in disbelief, 'Birds... get cancer?' That question convinced her the wall between animal and human medicine was an illusion. Fauna Bio's Convergence AI platform turns the survival tricks of extreme mammals into therapeutic targets, work that has drawn partnerships with Eli Lilly and Novo Nordisk and NASA-funded research into putting astronauts into a hibernation-like state.
Brad Berman
Brad Berman is the co-owner and CEO of BodyBio, a family-owned cellular-health and nutritional-supplement company in Millville, New Jersey. He arrived not from a lab but from the beverage aisle, with stops at PepsiCo and FIJI Water, and married into the founding Kane family. Since taking the top job in 2019 he has rebranded the 25-plus-year-old practitioner brand, pushed it into direct-to-consumer and mainstream retail, and steered roughly 41% revenue growth that landed BodyBio on the Inc. 5000.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.